DUBLIN, Ireland — Perrigo Co. has been cleared by the Food and Drug Administration to market over-the-counter guaifenesin and dextromethorphan hydrobromide extended-release tablets 1200 mg/60 mg, an expectorant and cough suppressant.

Perrigo said Wednesday that its guaifenesin and dextromethorphan ER tablets are an OTC generic version of Mucinex DM Maximum Strength tablets from Reckitt Benckiser.

Plans call for Perrigo’s product to be packaged and marketed as a store-brand or retailer “own label” item. The company said it’s now finalizing plans to release its store-brand Mucinex DM Maximum Strength for the 2018 cough and cold season.

“This final approval and upcoming launch is an important accomplishment for our OTC business,” stated Jeff Needham, executive vice president and president of Consumer Healthcare Americas at Perrigo. “Key product launches like Perrigo’s store-brand equivalent of Mucinex DM Maximum Strength provide our customers and consumers with high-quality, value alternatives in important treatment categories.”

Mucinex DM Maximum Strength is indicated to help control coughing and break up mucus, making coughs more productive.

Retail sales of Mucinex DM Maximum Strength totaled about $128 million over the previous 12 months, according to IRI market data reported by Perrigo.

Perrigo already offers store-brand versions of other Mucinex products, including for Mucinex DM, Mucinex ER and Mucinex D tablets.